Recruiting now
-
Neoadjuvant Chemoradiotherapy Followed by Chemotherapy With or Without Tislelizumab for Resectable Ultra-low Rectal Cancer: The RELIEVE-02 Study
Phase 3 · randomised · 196 people · 1 site in China · Recruiting now
-
Simultaneous Boost in Neoadjuvant Radiotherapy for Rectal Cancer
Phase 2 · randomised · 156 people · 1 site in China · Recruiting now
-
A Study of Botensilimab and Balstilimab for Colorectal Cancer With ctDNA+ After Surgery and Chemotherapy
Phase 2 · randomised · 284 people · 7 sites in United States · Recruiting now
-
Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma
Phase 3 · randomised · 108 people · 1 site in China · Recruiting now
-
Zanzalintinib Alone or in Combination With Pembrolizumab and Berahyaluronidase Alfa in Participants With Colorectal Cancer With Molecular Residual Disease
Phase 3 · randomised · 600 people · 13 sites in United States · Recruiting now
-
HDR Endorectal Brachytherapy With 3D-Printed Guidance and Local Shielding for Rectal Cancer Organ Preservation
Not phased · 50 people · 1 site in China · Recruiting now
-
FMT+ QL1706+Bevacizumab+ XELOX as First-line Treatment for Advanced MSS-type Colorectal Cancer With Liver Metastasis
Phase 2 · 30 people · 1 site in China · Recruiting now
-
Ivosidenib Plus mFOLFOXIRI and Celecoxib for BRAF-targeted Therapy-refractory BRAF V600E-mutant Colorectal Cancer Patients
Phase 2 · 45 people · 1 site in China · Recruiting now